Resumo

FERNANDEZ DELGADO, Norma  e  HERNANDEZ RAMIREZ, Porfirio. Myelodysplastic syndrome: I. Biology and Clinic. Rev Cubana Hematol Inmunol Hemoter [online]. 2000, vol.16, n.1, pp.5-20. ISSN 0864-0289.

Myelodysplastic syndromes (MDS) include a group of clonic disorders characterized by progressive cytopenias and dishematopoiesis. Etiology of primary MDS is unknow, and secondary ones may be due to use of antineoplastic agents, chemicals and in children, are related to constitutional diseases. Their general biological features include cytogenetic, molecular, and immunologic alterations accompaning hematopoiesis alterations. For diagnosis it is necessary 10% of cellular involvement in each serie, where dishematopoiesis be the cause. In 80% of bone marrow biopsies, we found signs of dismegacaryopoiesis and disarrangement in normal hematopoietic structure. Recently, it was proposed existence of MDS variants, including hyperfibrotic type, the early one, and MDS with features of myeloproliferative syndrome. Diagnosis of MDS is by exclusion and in differential diagnosis, it is necessary rule out some processes presenting myelodisplastic alterations, including anemias by vitamin B₁₂, folic acid, or piridoxin deficiency, chronic liver disease, chronic diseases anemia, chemotherapy, AIDS virus infection, and medullary aplasia, etc

Palavras-chave : MYELODYSPLASTIC SYNDROMES; ANTINEOPLASTIC AGENTS; MYELOPROLIFERATIVE DISORDERS; VITAMIN B₁₂ DEFICIENCY.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )